Opportunities and challenges of pluripotent stem cell neurodegenerative disease models

Nature Neuroscience

Volumn 16, Issue 7, 2013, Pages 780-789

  Sandoe, Jackson ^a,b   Eggan, Kevin ^a,b  

^a HARVARD UNIVERSITY   (United States)

^b Harvard University   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALZHEIMER DISEASE; CELL MATURATION; CELL RENEWAL; DEGENERATIVE DISEASE; DISEASE COURSE; DNA METHYLATION; DOPAMINERGIC NERVE CELL; GENE EXPRESSION; GENE MUTATION; GENE TARGETING; HOMOLOGOUS RECOMBINATION; HUMAN; HUNTINGTON CHOREA; IMMUNOCYTOCHEMISTRY; LESCH NYHAN SYNDROME; MOTONEURON; NERVE CELL CULTURE; NERVE CELL DIFFERENTIATION; NONHUMAN; NUCLEAR REPROGRAMMING; PARKINSON DISEASE; PHENOTYPE; PHENOTYPIC VARIATION; PLURIPOTENT STEM CELL; PLURIPOTENT STEM CELL LINE; PRIORITY JOURNAL; RETT SYNDROME; REVIEW; RNA SEQUENCE; SPINAL MUSCULAR ATROPHY; X CHROMOSOME INACTIVATION; ANIMAL; BIOLOGICAL MODEL; CELL DIFFERENTIATION; NERVE CELL; NEURODEGENERATIVE DISEASES; PHYSIOLOGY; TRANSPLANTATION;

ANIMALS; CELL DIFFERENTIATION; HUMANS; MODELS, BIOLOGICAL; NEURODEGENERATIVE DISEASES; NEURONS; PLURIPOTENT STEM CELLS;

EID: 84885850258     PISSN: 10976256     EISSN: 15461726     Source Type: Journal    
DOI: 10.1038/nn.3425     Document Type: Review

References (99)

1. Kiskinis, E. & Eggan, K. Progress toward the clinical application of patient-specific pluripotent stem cells. J. Clin. Invest. 120, 51-59 (2010).
2. Wichterle, H., Lieberam, I. & Porter, J. Directed differentiation of embryonic stem cells into motor neurons. Cell 110, 385-397 (2002).
3. Zhang, S.-C., Wernig, M., Duncan, I.D., Brustle, O. & Thomson, J.A. In vitro differentiation of transplantable neural precursors from human embryonic stem cells. Nat. Biotechnol. 19, 1129-1133 (2001).
4. Murry, C.E. & Keller, G. Differentiation of embryonic stem cells to clinically relevant populations: lessons from embryonic development. Cell 132, 661-680 (2008).
5. Bellin, M., Marchetto, M.C., Gage, F.H. & Mummery, C.L. Induced pluripotent stem cells: the new patient? Nat. Rev. Mol. Cell Biol. 13, 713-726 (2012).
6. Takahashi, K. et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 131, 861-872 (2007).
7. Dimos, J.T. et al. Induced pluripotent stem cells generated from patients with ALS can be differentiated into motor neurons. Science 321, 1218-1221 (2008).
8. Park, I.H. et al. Disease-specific induced pluripotent stem cells. Cell 134, 877-886 (2008).
9. Liu, G.-H. et al. Progressive degeneration of human neural stem cells caused by pathogenic LRRK2. Nature 491, 603-607 (2012).
10. Han, S.S.W., Williams, L.A. & Eggan, K.C. Constructing and deconstructing stem cell models of neurological disease. Neuron 70, 626-644 (2011).
11. Yagi, T. et al. Modeling familial Alzheimer's disease with induced pluripotent stem cells. Hum. Mol. Genet. 20, 4530-4539 (2011).
12. Sánchez-Danés, A. et al. Disease-specific phenotypes in dopamine neurons from human iPS-based models of genetic and sporadic Parkinson's disease. EMBO Mol. Med. 80, 380-395 (2012).
13. Jeon, I. et al. Neuronal properties, in vivo effects, and pathology of a Huntington's disease patient-derived induced pluripotent stem cells. Stem Cells 30, 2054-2062 (2012).
14. Ebert, A.D. et al. Induced pluripotent stem cells from a spinal muscular atrophy patient. Nature 457, 277-280 (2009).
15. Mekhoubad, S. et al. Erosion of dosage compensation impacts human iPSC disease modeling. Cell Stem Cell 10, 595-609 (2012).
16. Marchetto, M.C.N. et al. A model for neural development and treatment of Rett syndrome using human induced pluripotent stem cells. Cell 143, 527-539 (2010).
17. Brennand, K.J. et al. Modelling schizophrenia using human induced pluripotent stem cells. Nature 473, 221-225 (2011).
18. Boulting, G.L. et al. A functionally characterized test set of human induced pluripotent stem cells. Nat. Biotechnol. 29, 279-286 (2011).
19. Xu, C. et al. Feeder-free growth of undifferentiated human embryonic stem cells. Nat. Biotechnol. 19, 971-974 (2001).
20. Chen, A.E. et al. Optimal timing of inner cell mass isolation increases the efficiency of human embryonic stem cell derivation and allows generation of sibling cell lines. Cell Stem Cell 4, 103-106 (2009).
21. Thomson, J.A. et al. Embryonic stem cell lines derived from human blastocysts. Science 282, 1145-1147 (1998).
22. Di Giorgio, F.P., Boulting, G., Bobrowicz, S. & Eggan, K. Human embryonic stem cell-derived motor neurons are sensitive to the toxic effect of glial cells carrying an ALS-causing mutation. Cell Stem Cell 3, 637-648 (2008).
23. Marchetto, M.C.N. et al. Non-cell-autonomous effect of human SOD1 G37R astrocytes on motor neurons derived from human embryonic stem cells. Cell Stem Cell 3, 649-657 (2008).
24. Verlinsky, Y. et al. Human embryonic stem cell lines with genetic disorders. Reprod. Biomed. Online 10, 105-110 (2005).
25. Mateizel, I. et al. Derivation of human embryonic stem cell lines from embryos obtained after IVF and after PGD for monogenic disorders. Hum. Reprod. 21, 503-511 (2006).
26. Yu, J. et al. Induced pluripotent stem cell lines derived from human somatic cells. Science 318, 1917-1920 (2007).
27. Chin, M.H. et al. Induced pluripotent stem cells and embryonic stem cells are distinguished by gene expression signatures. Cell Stem Cell 5, 111-123 (2009).
28. Müller, F.-J. et al. A bioinformatic assay for pluripotency in human cells. Nat. Methods 8, 315-317 (2011).
29. Bock, C. et al. Reference maps of human ES and iPS cell variation enable high-throughput characterization of pluripotent cell lines. Cell 144, 439-452 (2011).
30. Tomoda, K. et al. Derivation conditions impact X-inactivation status in female human induced pluripotent stem cells. Cell Stem Cell 11, 91-99 (2012).
31. Ohi, Y. et al. Incomplete DNA methylation underlies a transcriptional memory of somatic cells in human iPS cells. Nat. Cell Biol. 13, 541-549 (2011).
32. Daley, G.Q. et al. Broader implications of defining standards for the pluripotency of iPSCs. Cell Stem Cell 4, 200-201 (2009).
33. Lister, R. et al. Hotspots of aberrant epigenomic reprogramming in human induced pluripotent stem cells. Nature 471, 68-73 (2011).
34. Marchetto, M.C.N. et al. Transcriptional signature and memory retention of human-induced pluripotent stem cells. PLoS ONE 4, e7076 (2009).
35. Polo, J.M. et al. Cell type of origin influences the molecular and functional properties of mouse induced pluripotent stem cells. Nat. Biotechnol. 28, 848-855 (2010).
36. Silva, S.S., Rowntree, R.K., Mekhoubad, S. & Lee, J.T. X-chromosome inactivation and epigenetic fluidity in human embryonic stem cells. Proc. Natl. Acad. Sci. USA 105, 4820-4825 (2008).
37. Osafune, K. et al. Marked differences in differentiation propensity among human embryonic stem cell lines. Nat. Biotechnol. 26, 313-315 (2008).
38. Hu, B., Weick, J., Yu, J. & Ma, L. Neural differentiation of human induced pluripotent stem cells follows developmental principles but with variable potency. Proc. Natl. Acad. Sci. USA 107, 4335-4340 (2010).
39. Kondo, T. et al. Modeling Alzheimer's disease with iPSCs reveals stress phenotypes associated with intracellular A? and differential drug responsiveness. Cell Stem Cell 12, 487-496 (2013).
40. Huntington's Consortium. Induced pluripotent stem cells from patients with Huntington's disease show CAG-repeat-expansion-associated phenotypes. Cell Stem Cell 11, 264-278 (2012).
41. Chang, T. et al. Brief report: phenotypic rescue of induced pluripotent stem cell-derived motoneurons of a spinal muscular atrophy patient. Stem Cells 29, 2090-2093 (2011).
42. Soldner, F. et al. Generation of isogenic pluripotent stem cells differing exclusively at two early onset Parkinson point mutations. Cell 146, 318-331 (2011).
43. An, M.C. et al. Genetic correction of Huntington's disease phenotypes in induced pluripotent stem cells. Cell Stem Cell 11, 253-263 (2012).
44. Khan, I.F., Hirata, R.K. & Russell, D.W. AAV-mediated gene targeting methods for human cells. Nat. Protoc. 6, 482-501 (2011).
45. Aizawa, E. et al. Efficient and accurate homologous recombination in hESCs and hiPSCs using helper-dependent adenoviral vectors. Mol. Ther. 20, 424-431 (2012).
46. Andersen, M.S., Sørensen, C.B., Bolund, L. & Jensen, T.G. Mechanisms underlying targeted gene correction using chimeric RNA/DNA and single-stranded DNA oligonucleotides. J. Mol. Med. 80, 770-781 (2002).
47. Zou, J. et al. Gene targeting of a disease-related gene in human induced pluripotent stem and embryonic stem cells. Cell Stem Cell 5, 97-110 (2009).
48. Mali, P. et al. RNA-guided human genome engineering via Cas9. Science 339, 823-826 (2013).
49. Hockemeyer, D. et al. Genetic engineering of human pluripotent cells using TALE nucleases. Nat. Biotechnol. 29, 731-734 (2011).
50. Urnov, F.D., Rebar, E.J., Holmes, M.C., Zhang, H.S. & Gregory, P.D. Genome editing with engineered zinc finger nucleases. Nat. Rev. Genet. 11, 636-646 (2010).
51. Reinhardt, P. et al. Genetic correction of a LRRK2 mutation in human iPSCs links Parkinsonian neurodegeneration to ERK-dependent changes in gene expression. Cell Stem Cell 12, 354-367 (2013).
52. Corti, S. et al. Genetic correction of human induced pluripotent stem cells from patients with spinal muscular atrophy. Sci. Transl. Med. 4, 165ra162 (2012).
53. Lombardo, A. et al. Site-specific integration and tailoring of cassette design for sustainable gene transfer. Nat. Methods 8, 861-869 (2011).
54. Yusa, K. et al. Targeted gene correction of ?1-antitrypsin deficiency in induced pluripotent stem cells. Nature 478, 391-394 (2011).
55. Qiurong, D. et al. A TALEN genome-editing system for generating human stem cell-based disease models. Cell Stem Cell 12, 238-251 (2012).
56. Kanning, K.C., Kaplan, A. & Henderson, C.E. Motor neuron diversity in development and disease. Annu. Rev. Neurosci. 33, 409-440 (2010).
57. Chambers, S.M. et al. Combined small-molecule inhibition accelerates developmental timing and converts human pluripotent stem cells into nociceptors. Nat. Biotechnol. 30, 715-720 (2012).
58. Wataya, T. et al. Minimization of exogenous signals in ES cell culture induces rostral hypothalamic differentiation. Proc. Natl. Acad. Sci. USA 105, 11796-11801 (2008).
59. Kriks, S. et al. Dopamine neurons derived from human ES cells efficiently engraft in animal models of Parkinson's disease. Nature 418, 50-56 (2011).
60. Yuan, S.H. et al. Cell-surface marker signatures for the isolation of neural stem cells, glia and neurons derived from human pluripotent stem cells. PLoS ONE 6, e17540 (2011).
61. Di Giorgio, F.P., Carrasco, M., Siao, M., Maniatis, T. & Eggan, K. Non-cell autonomous effect of glia on motor neurons in an embryonic stem cell-based ALS model. Nat. Neurosci. 10, 608-614 (2007).
62. Lobsiger, C.S. & Cleveland, D.W. Glial cells as intrinsic components of non-cell-autonomous neurodegenerative disease. Nat. Neurosci. 10, 1355-1360 (2007).
63. Amoroso, M.W. et al. Accelerated high-yield generation of limb-innervating motor neurons from human stem cells. J. Neurosci. 33, 574-586 (2013).
64. Bilican, B. et al. Mutant induced pluripotent stem cell lines recapitulate aspects of TDP-43 proteinopathies and reveal cell-specific vulnerability. Proc. Natl. Acad. Sci. USA 109, 5803-5808 (2012).
65. Hockemeyer, D. et al. Efficient targeting of expressed and silent genes in human ESCs and iPSCs using zinc-finger nucleases. Nat. Biotechnol. 27, 851-857 (2009).
66. Sergent-Tanguy, S., Chagneau, C., Neveu, I. & Naveilhan, P. Fluorescent activated cell sorting (FACS): a rapid and reliable method to estimate the number of neurons in a mixed population. J. Neurosci. Methods 129, 73-79 (2003).
67. Vodyanik, M.A., Thomson, J.A. & Slukvin, I.I. Leukosialin (CD43) defines hematopoietic progenitors in human embryonic stem cell differentiation cultures. Blood 108, 2095-2105 (2006).
68. Singh Roy, N. et al. Enhancer-specified GFP-based FACS purification of human spinal motor neurons from embryonic stem cells. Exp. Neurol. 196, 224-234 (2005).
69. Molyneaux, B.J., Arlotta, P., Menezes, J.R.L. & Macklis, J.D. Neuronal subtype specification in the cerebral cortex. Nat. Rev. Neurosci. 8, 427-437 (2007).
70. Dawson, T.M. & Dawson, V.L. Neuroprotective and neurorestorative strategies for Parkinson's disease. Nat. Neurosci. 5, 1058-1061 (2002).
71. Nunes, I., Tovmasian, L.T., Silva, R.M., Burke, R.E. & Goff, S.P. Pitx3 is required for development of substantia nigra dopaminergic neurons. Proc. Natl. Acad. Sci. USA 100, 4245-4250 (2003).
72. von Steyern, F.V. et al. The homeodomain transcription factors Islet 1 and HB9 are expressed in adult alpha and gamma motoneurons identified by selective retrograde tracing. Eur. J. Neurosci. 11, 2093-2102 (1999).
73. Takazawa, T. et al. Maturation of spinal motor neurons derived from human embryonic stem cells. PLoS ONE 7, e40154 (2012).
74. Kim, J.E. et al. Investigating synapse formation and function using human pluripotent stem cell-derived neurons. Proc. Natl. Acad. Sci. USA 108, 3005-3010 (2011).
75. Shi, Y., Kirwan, P., Smith, J., Robinson, H.P.C. & Livesey, F.J. Human cerebral cortex development from pluripotent stem cells to functional excitatory synapses. Nat. Neurosci. 15, 477-486 (2012).
76. Delaloy, C. et al. MicroRNA-9 coordinates proliferation and migration of human embryonic stem cell-derived neural progenitors. Cell Stem Cell 6, 323-335 (2010).
77. Juurlink, B.H.J. & Walz, W. Neural cell culture techniques. Neuromethods 33, 53-102 (1998).
78. Pang, Z.P. et al. Induction of human neuronal cells by defined transcription factors. Nature 476, 220-223 (2011).
79. Son, E.Y. et al. Conversion of mouse and human fibroblasts into functional spinal motor neurons. Cell Stem Cell 9, 205-218 (2011).
80. Hester, M. et al. Rapid and efficient generation of functional motor neurons from human pluripotent stem cells using gene delivered transcription factor codes. Mol. Ther. 19, 1905-1912 (2011).
81. Christopherson, K.S. et al. Thrombospondins are astrocyte-secreted proteins that promote CNS synaptogenesis. Cell 120, 421-433 (2005).
82. Keller, J.N., Huang, F. & Markesbery, W. Decreased levels of proteasome activity and proteasome expression in aging spinal cord. Neuroscience 98, 149-156 (2000).
83. Erraji-Benchekroun, L. et al. Molecular aging in human prefrontal cortex is selective and continuous throughout adult life. Biol. Psychiatry 57, 549-558 (2005).
84. Cheung, I. et al. Developmental regulation and individual differences of neuronal H3K4me3 epigenomes in the prefrontal cortex. Proc. Natl. Acad. Sci. USA 107, 8824-8829 (2010).
85. Wong, E. & Cuervo, A.M. Autophagy gone awry in neurodegenerative diseases. Nat. Neurosci. 13, 805-811 (2010).
86. Matus, S., Glimcher, L.H. & Hetz, C. Protein folding stress in neurodegenerative diseases: a glimpse into the ER. Curr. Opin. Cell Biol. 23, 239-252 (2011).
87. Alegre-Abarrategui, J., Ansorge, O., Esiri, M. & Wade-Martins, R. LRRK2 is a component of granular alpha-synuclein pathology in the brainstem of Parkinson's disease. Neuropathol. Appl. Neurobiol. 34, 272-283 (2008).
88. Shi, Y. et al. A human stem cell model of early Alzheimer's disease pathology in Down syndrome. Sci. Transl. Med. 4, 124ra129 (2012).
89. Egawa, N. et al. Drug screening for ALS using patient-specific induced pluripotent stem cells. Sci. Transl. Med. 4, 145ra104 (2012).
90. Cooper, O. et al. Pharmacological rescue of mitochondrial deficits in iPSC-derived neural cells from patients with familial Parkinson's disease. Sci. Transl. Med. 4, 141ra190 (2012).
91. Koch, P. et al. Excitation-induced ataxin-3 aggregation in neurons from patients with Machado-Joseph disease. Nature. 480, 543-546 (2011).
92. Nguyen, H.N. et al. LRRK2 mutant iPSC-derived DA neurons demonstrate increased susceptibility to oxidative stress. Cell Stem Cell 8, 267-280 (2011).
93. Fabian, M.A. et al. A small molecule-kinase interaction map for clinical kinase inhibitors. Nat. Biotechnol. 23, 329-336 (2005).
94. Double, K.L., Reyes, S., Werry, E. & Halliday, G. Selective cell death in neurodegeneration: why are some neurons spared in vulnerable regions? Prog. Neurobiol. 92, 316-329 (2010).
95. Saxena, S., Cabuy, E. & Caroni, P. A role for motoneuron subtype-selective ER stress in disease manifestations of FALS mice. Nat. Neurosci. 12, 627-636 (2009).
96. Rosen, D.R. et al. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 362, 59-62 (1993).
97. Brockington, A. et al. Unravelling the enigma of selective vulnerability in neurodegeneration: motor neurons resistant to degeneration in ALS show distinct gene expression characteristics and decreased susceptibility to excitotoxicity. Acta Neuropathol.125, 95-109 (2013).
98. Renton, A.E. et al. A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron 72, 257-268 (2011).
99. Seeley, W.W. et al. Early frontotemporal dementia targets neurons unique to apes and humans. Ann. Neurol. 60, 660-667 (2006).